NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
06 Fevereiro 2024 - 10:28AM
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company
focused on designing, developing, and marketing products that
improve the quality of life for patients who suffer from
neurohealth disorders, announced criteria changes by Lucet Health
that increase access for patients with depression to receive
transcranial magnetic stimulation (TMS), such as NeuroStar®
Advanced Therapy. The policy update reduces the number of
antidepressant medication attempts from four down to two prior to
TMS eligibility.
“I am pleased to witness the collective efforts leading to
improved access to mental health coverage,” stated Keith J.
Sullivan, President and CEO of Neuronetics, Inc. “We commend Lucet
Health for recognizing the importance of ensuring that individuals
can access proven treatments like NeuroStar earlier in their path
towards wellness.”
Lucet Health is a behavioral health organization that works with
large insurance carriers across the country. Its policies impact
approximately 9 million covered lives. The updated TMS criteria are
effective as of February 1, 2024.
Neuronetics also recently announced continued momentum for
favorable TMS coverage changes through three additional payors.
Neuronetics is the only TMS company in the industry with a
dedicated health policy team that partners with both providers and
payors to advocate for health policy changes.
For more information about NeuroStar TMS Therapy, visit
www.NeuroStar.com.
About NeuroneticsNeuronetics, Inc. believes
that mental health is as important as physical health. As a global
leader in neuroscience, Neuronetics is redefining patient and
physician expectations with its NeuroStar Advanced Therapy for
Mental Health. NeuroStar is a non-drug, noninvasive treatment that
can improve the quality of life for people suffering from
neurohealth conditions when traditional medication hasn’t helped.
In the United States, NeuroStar is FDA-cleared for adults with
major depressive disorder (MDD), as an adjunct for adults with
obsessive-compulsive disorder (OCD), and to decrease anxiety
symptoms in adult patients with MDD that may exhibit comorbid
anxiety symptoms (anxious depression). NeuroStar Advanced Therapy
is the leading transcranial magnetic stimulation (TMS) treatment
for MDD in adults with over 5.9 million treatments delivered.
NeuroStar is backed by the largest clinical data set of any TMS
system for depression, including the world’s largest depression
Outcomes Registry. Neuronetics is committed to transforming lives
by offering an exceptional treatment that produces extraordinary
results. For safety and prescribing information,
www.NeuroStar.com.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024